Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This transcript, annotated as “novel transcript, antisense to PILRA” (Ensembl Gene ID ENSG00000287631), is a long non-coding RNA discovered via genome-wide annotation and is situated antisense to the coding region for the PILRA gene. Its sequence overlaps portions of PILRA, a paired immunoglobulin-like type 2 receptor alpha involved in immune regulation and viral entry. However, the antisense transcript itself does not code for a protein and currently lacks characterized molecular function, clinical relevance, or associations with disease. It may have regulatory or structural roles in the genome, but these have not been experimentally validated or described in functional databases to date[5]. Key Notes: - It is not equivalent to PILRA, which is a well-characterized immune inhibitory receptor protein implicated in various disease pathways such as inflammation, neurodegeneration, and infection[2][3][4][6][7][8]. The “novel transcript, antisense to PILRA” is strictly non-coding and currently of unknown function. - Its designation as “antisense to PILRA” may eventually become more meaningful if future research identifies a regulatory relationship, but at present, it remains an “uncharacterized, novel” entity in genome annotation[5]. Further annotation or protein information should be sought for PILRA itself, not ENSG00000287631, if a therapeutic or functional molecular target is required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to PILRA.